• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Dalcetrapib

CAS No. 211513-37-0

Dalcetrapib ( JTT-705 | JTT705 | JTT 705 | RO-4607381 )

产品货号. M17429 CAS No. 211513-37-0

Dalcetrapib 是一种 rhCETP 抑制剂 (IC50=0.2 μM),可增加血浆 HDL 胆固醇。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥300 有现货
5MG ¥462 有现货
10MG ¥583 有现货
25MG ¥1094 有现货
50MG ¥1709 有现货
100MG ¥2989 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Dalcetrapib
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Dalcetrapib 是一种 rhCETP 抑制剂 (IC50=0.2 μM),可增加血浆 HDL 胆固醇。
  • 产品描述
    Dalcetrapib, aslo known as JTT-705, is a CETP inhibitor. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health. Development of this drug was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.(In Vitro):Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.(In Vivo):Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol.
  • 体外实验
    Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.
  • 体内实验
    Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol. Animal Model:Male JW rabbits Dosage:30 or 100 mg/kg Administration:Oral administration, once a day for 3 days Result:Increased plasma HDL cholesterol by 27% and 54% at 30 mg/kg and 100 mg/kg, respectively.
  • 同义词
    JTT-705 | JTT705 | JTT 705 | RO-4607381
  • 通路
    Angiogenesis
  • 靶点
    FGFR
  • 受体
    rhCETP
  • 研究领域
    Cardiovascular Disease|Metabolic Disease
  • 适应症
    ——

化学信息

  • CAS Number
    211513-37-0
  • 分子量
    389.59
  • 分子式
    C23H35NO2S
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO : ≥ 50 mg/mL. 128.34 mM; H2O : < 0.1 mg/mL
  • SMILES
    c1(ccccc1NC(=O)C1(CC(CC)CC)CCCCC1)SC(=O)C(C)C
  • 化学全称
    S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Niesor EJ, et al. J Lipid Res. 2010, 51(12), 3443-3454.
产品手册
关联产品
  • FGF-401

    FGF-401(NVP-FGF401、Roblitinib、FGF401)是一种一流的、有效的、高选择性的 FGFR4 抑制剂,IC50 为 1.1 nM。

  • Palifosfamide

    帕利磷酰胺赖氨酸 (ZIO-201) 是帕利磷酰胺的稳定形式。 Palifosfamide lysine 在体外对肉瘤系具有广泛的活性。

  • AZD4547

    一种有效的选择性 FGFR1/2/3 抑制剂,IC50 为 0.2/1.8/2.5 nM。